A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma (ESCC)
Interventions:   Drug: BGB-A317;   Drug: Paclitaxel, or Docetaxel, or Irinotecan
Sponsor:   BeiGene
Recruiting

http://ift.tt/2o2CMeP